米拉贝隆作为治疗膀胱过度活动症的新型口服药物：诸多积极方面，也存在一些担忧。 - Suppr

Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns.

作者信息

Novara Giacomo, Cornu Jean-Nicolas

出版信息

Eur Urol. 2013 Feb;63(2):306-8. doi: 10.1016/j.eururo.2012.11.024. Epub 2012 Nov 16.

DOI:10.1016/j.eururo.2012.11.024

PMID:23201469

Abstract

摘要

相似文献

Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns.

Eur Urol. 2013 Feb;63(2):306-8. doi: 10.1016/j.eururo.2012.11.024. Epub 2012 Nov 16.

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

Eur Urol. 2013 Feb;63(2):283-95. doi: 10.1016/j.eururo.2012.10.016. Epub 2012 Nov 6.

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.

Eur Urol. 2013 Feb;63(2):296-305. doi: 10.1016/j.eururo.2012.10.048. Epub 2012 Nov 6.

Flexible dose fesoterodine in the treatment of overactive bladder (OAB).

BJU Int. 2013 Aug;112(3):281-2. doi: 10.1111/bju.12319.

Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron.

J Med Econ. 2013 Jul;16(7):866-76. doi: 10.3111/13696998.2013.802240. Epub 2013 May 20.

The role of mirabegron in overactive bladder: a systematic review and meta-analysis.

Urol Int. 2014;93(3):326-37. doi: 10.1159/000361079. Epub 2014 Aug 7.

Treatment of men with lower urinary tract symptoms and overactive bladder.

JAMA. 2007 Mar 21;297(11):1192; author reply 1193. doi: 10.1001/jama.297.11.1192-a.

Overactive bladder disease: the urge for better therapies.

J Manag Care Pharm. 2008 May;14(4):381-6. doi: 10.18553/jmcp.2008.14.4.381.

Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.

Int J Urol. 2014 Oct;21(10):960-7. doi: 10.1111/iju.12568. Epub 2014 Aug 4.

Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.

J Urol. 2006 Nov;176(5):2311-2; author reply 2312-3. doi: 10.1016/j.juro.2006.06.053.

引用本文的文献

Efficacy and safety of mirabegron in the treatment of overactive bladder syndrome after radical prostatectomy: a prospective randomized controlled study.

Front Oncol. 2023 May 2;13:1188619. doi: 10.3389/fonc.2023.1188619. eCollection 2023.

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.

Int J Clin Pract. 2017 Mar;71(3-4). doi: 10.1111/ijcp.12824.

Postmenopausal overactive bladder.

Prz Menopauzalny. 2014 Dec;13(6):313-29. doi: 10.5114/pm.2014.47984. Epub 2014 Dec 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns.

作者信息

出版信息

相似文献

引用本文的文献